4à6: UCB Farchim SA (05.10.2010, Fribourg)You are hereAbout BioAlpsPhoto galleryArchives photo gallery4à6: UCB Farchim SA (05.10.2010, Fribourg)4à6: UCB Farchim SA (05.10.2010, Fribourg)
Find an actor
Journée de l'Innovation 2017 aux HUG Jeudi 19 octobre19.10.201711ème Journée de l’innovation au Centre de l’innovation des HUG. Conférences, concours de pitchs, remise des...
Pryv SA closes 1.1M CHF Pre-Series A to accelerate growth and prepare Series A funding roundPryv SA, an independent Swiss Health-IT company, specialized in providing innovative data management and digital...
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.